Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Minigastrin

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Debiopharm International & Paul Scherrer Institute Announce Licensing Agreement
    Debiopharm International & Paul Scherrer Institute Announce Licensing Agreement

    11 Oct 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/debiopharm-international-sa-and-the-paul-scherrer-institute-announce-a-licensing-agreement-for-the-development-of-a-novel-targeted-radiotherapeutic-product-in-oncology-300729254.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share
    Debiopharm International & Paul Scherrer Institute Announce Licensing Agreement
    Debiopharm International & Paul Scherrer Institute Announce Licensing Agreement

    11 Oct 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/debiopharm-international-sa-and-the-paul-scherrer-institute-announce-a-licensing-agreement-for-the-development-of-a-novel-targeted-radiotherapeutic-product-in-oncology-300729254.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share
    Debiopharm International & Paul Scherrer Institute Announce Licensing Agreement
    Debiopharm International & Paul Scherrer Institute Announce Licensing Agreement

    11 Oct 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/debiopharm-international-sa-and-the-paul-scherrer-institute-announce-a-licensing-agreement-for-the-development-of-a-novel-targeted-radiotherapeutic-product-in-oncology-300729254.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share